A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Pfizer
CSPC Megalith Biopharmaceutical Co.,Ltd.
University College, London
EMD Serono
Institut Català d'Oncologia
European Organisation for Research and Treatment of Cancer - EORTC
AstraZeneca
Northwestern University
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center